Table II.

Efficacy of Olmesartan Medoxomil (OM) and OM/HCTZ in the Total Patient Population (Efficacy Cohort)

Week/Treatment
Efficacy Measure, mm Hg	3/OM 20 mg/d (N=169)	6/OM 40 mg/d (n=160)	9/OM/HCTZ 40/12.5mg/d (n=157)	12/OM/HCTZ 40/25 mg/d (n=143)
Baseline SBP/DBP, mean	171.4/95.2	171.3/95.4	171.4/95.4	171.4/95.7
δSBP, mean (SD)*	−16.9 (14.3)†	−18.4 (15.3)†	−30.3 (15.0)†	−34.5 (14.4)†
δDBP, mean (SD)*	−5.5 (8.4)†	−6.8 (7.7)†	−11.5 (9.1)†	−13.7 (8.9)†
BP <140/90, %†	15.4	29.0	55.6	70.4
BP <120/80, %†	1.2	1.2	5.9	15.4
*Last observation carried forward. †P<.001 vs baseline. † Cumulative (percentage of the total number of patients in the efficacy cohort). HCTZ indicates hydrochlorothiazide; SBP, systolic blood pressure (BP); DBP, diastolic BP; and δ, change.